Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: Prevalence, risk factors and relationship to liver disease

F. Fabrizi, D. Marcelli, G. Bacchini, I. Guarnori, G. Erba, F. Locatelli

Research output: Contribution to journalArticlepeer-review

Abstract

There are no data regarding HCV prevalence in CRF patients not requiring dialysis. In order to assess prevalence and risk factors for HCV infection in CRF patients on conservative therapy we tested, by second-generation assays such as Ortho 2 and 4-RIBA, 221 predialysis CRF patients attending our Department. Forty-four (20%) patients were anti-HCV positive. Anti-HCV positivity was related to blood transfusion requirement, past or current elevations of transaminase levels and, to a lesser degree, CRF duration. The prevalence of anti-HCV positivity among CRF patients who were never transfused was about 10 times higher than that of blood donors. Our data show that predialysis CRF patients should be considered a specific risk group for HCV infection; blood transfusion history and duration of CRF are risk factors for acquisition of HCV infection; HCV infection may play a role in the development of liver disease in this clinical setting.

Original languageEnglish
Pages (from-to)780-784
Number of pages5
JournalNephrology Dialysis Transplantation
Volume9
Issue number7
Publication statusPublished - 1994

Keywords

  • Anti-HCV antibodies
  • Hepatitis C virus
  • Renal failure

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: Prevalence, risk factors and relationship to liver disease'. Together they form a unique fingerprint.

Cite this